Abstract 128P
Background
Gastric cancer is the fifth most frequently diagnosed cancer and the third leading cause of cancer-related deaths in the world. Gastric cancer still constitutes a major global health problem in Asian countries; however there is limited data of the clinical outcome of gastric cancer in the Philippines. Thus this study aimed to determine the survival outcome of gastric adenocarcinoma patients in our institution.
Methods
This was a single-center 10-year retrospective study of gastric adenocarcinoma patients in our institution from January 2010 to December 2019. Categorical data were reported as number with percentage and continuous variables were reported as median. Survival outcomes were calculated using Kaplan-Meier method. Cox proportional hazards (PH) model was used to estimate the effect of variables on event-free survival (EFS) and overall survival (OS). P value of < 0.05 was set to indicate a statistically significant difference.
Results
Median age of diagnosis was 57 years old (range 20 to 86 years old). The majority (78%) of patients were younger than 70 years old and majority were males (62.1%). Abdominal pain was the most common presenting symptom. Patients had stage III (25.8%) and stage IV (54.5%) at diagnosis. Liver was the most common site of metastasis. Most gastric lesions were located at the proximal third (cardia and gastroesophageal area), poorly differentiated, diffuse type, Her2 negative, H.pylori negative. Majority of patients had normal body mass index, no comorbidities, and were non-smokers. Median overall event-free survival (EFS) for all patients was 7.1 months (95% CI 4.8 to 9.4) and median overall survival (OS) was 8.7 months (95% CI 6.4 to 11.1). Using multivariable analysis, the predictors for both EFS and OS were stage at diagnosis, Lauren’s histologic classification and smoking status.
Conclusions
Survival outcome of gastric cancer patients in our institution is similar to that in other Asian countries. Advanced stage at diagnosis was largely responsible for low survival. Early screening and patient education are needed to help improve survival outcome.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
79P - Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase III HIMALAYA study
Presenter: Arndt Vogel
Session: Poster viewing 02
82P - A randomized controlled, open-label, adaptive phase III clinical trial to evaluate safety and efficacy of EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas after FOLFIRINOX
Presenter: Muh-Hwan Su
Session: Poster viewing 02
83P - Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster viewing 02
84P - Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large real life worldwide population
Presenter: Margherita Rimini
Session: Poster viewing 02
86P - Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study
Presenter: Aiwu Ruth He
Session: Poster viewing 02
87P - Socio-demographic disparities in esophageal cancer: A SEER analysis
Presenter: Beas Siromoni
Session: Poster viewing 02